All In Biotech

NDA 213189 · Almirall

Klisyri

Tirbanibulin · Topical · Microtubule Inhibitor

Novel

Last checked: Nov 20, 2026Latest source record: Jun 7, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Dec 14, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

17

3 Phase 3, 3 recruiting

FAERS reports

249

49 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 24, 2026.

KLISYRI is indicated for the topical field treatment of actinic keratosis on the face or scalp. KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp. ( 1 )

Mechanism: Tirbanibulin is a microtubule inhibitor. The mechanism of action of KLISYRI for the topical treatment of actinic keratosis is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • KLISYRI · TIRBANIBULIN 1% · OINTMENT, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tirbanibulin" as an intervention, any sponsor and status, largest first.

All 17 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective48
  • application site erythema36
  • erythema25
  • drug intolerance20
  • adverse drug reaction17
  • application site exfoliation17
  • application site vesicles16
  • off label use15
  • application site pain13
  • pruritus12
  • application site dryness10
  • application site pruritus10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20191
20217
202265
202327
202479
202539
202631

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Klisyri (Tirbanibulin)

2024 spending

$3.4M

Beneficiaries

2,207

2,868 claims

Per beneficiary

$1,560

$224.52 per unit

View as table
YearSpending
2020$0
2021$1,153,842
2022$2,124,928
2023$3,001,296
2024$3,443,218

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 14 on PubMed

Sponsor: Almirall

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.